Research & Development

Navigating material demands of next-gen CGTs
Wednesday, April 01, 2026
Cultivating resilient, stage-appropriate supply strategies is an essential yet often overlooked part of delivering safe, effective therapies to patients. read more
Electroporation-based delivery for gene editing
Wednesday, March 25, 2026
New findings establish the feasibility of combining nonviral ex vivo gene editing, hepatocyte transplantation, and in vivo selection, and support the clinical translation... read more
Rethinking iPSC development
Wednesday, September 10, 2025
A robust CMC strategy cannot be retrofitted; it should guide decisions from the very beginning. For developers aiming to bring iPSC-based therapies to the commercial ... read more
Are LNPs the new AAV?
Wednesday, August 27, 2025
The emergence of nonviral vectors represents an opportunity to propel in vivo gene therapy further into commercial adoption and expand its impact globally. LNPs are ... read more
Navigating the realities of CAR-T cell oncology trials
Wednesday, August 20, 2025
Given the undeniably novel aspect of this new paradigm, however, conducting CAR-T clinical trials presents a unique set of obstacles for sponsors, sites and regulators to... read more

Legend opens new cell therapy R&D facility in Philly
The 31,000-square-foot facility is now fully operational and will support Legend’s expanding pipeline of next-generation cell therapies.
Thursday, November 13, 2025
Orbital unveils preclinical in vivo CAR-T data for autoimmune disease
OTX-201 achieved full B cell depletion in blood, spleen, and lymph nodes in a non-human primate study.
Wednesday, July 23, 2025
Vertex shares updated data for islet cell therapy in diabetes
All patients who received a full dose of zimislecel achieved ADA-recommended target HbA1c levels and 10/12 patients were insulin free.
Monday, June 23, 2025